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Abstract
Pharmacological inhibitors that block amyloid precursor protein (APP) cleavage and the formation of
senile plaques are under development for the treatment of familial Alzheimer’s disease. Unfortunately,
many inhibitors that block g-secretase-mediated cleavage of APP also have immunosuppressive side
effects. In addition to APP, numerous other proteins undergo g-secretase-mediated cleavage. In order
to develop safer inhibitors, it is necessary to determine which of the g-secretase substrates
contribute to the immunosuppressive effects. Because APP family members are widely expressed
and are reported to inﬂuence calcium ﬂux, transcription and apoptosis, they could be important for
normal lymphocyte maturation. We ﬁnd that APP and amyloid precursor-like protein 2 are expressed
by stromal cells of thymus and lymph nodes, but not by lymphocytes. Although signals provided by
thymic stromal cells are critical for normal T cell differentiation, lymphocyte development proceeds
unperturbed in mice deﬁcient for these APP family members.
Introduction
The major protein component of the senile plaques associ-
ated with familial Alzheimer’s disease is the Ab peptide that
is generated when amyloid precursor protein (APP) under-
goes sequential b- and c-secretase-mediated cleavages.
There has been a great deal of interest in the use of pharma-
cological c-secretase inhibitors for treatment of Alzheimer’s
disease, based on the hypothesis that preventing cleavage
of APP could potentially cure the disease. Unfortunately,
c-secretase inhibitors can have immunosuppressive side
effects. Inclusion of c-secretase inhibitors in fetal thymus or-
gan cultures profoundly blocked thymocyte development
(1,2). Moreover, c-secretase inhibitors impaired proliferation
and cytokine production by mature T cells in vitro (3–7).
Numerous proteins undergo c-secretase-mediated cleav-
age including APPs, Notch 1-4, Delta1, Jagged2, CD44,
ErbB4, E-cadherin, lipoprotein receptor-related protein
(LRP), Nectin-1a and chemokines CX3CL1 and CXCL16
(8–18). These proteins are variably expressed in lymphocytes
and lymphoid-associated stromal cells. The c-secretase
inhibitors that were used in experiments for impairing T cell
responses and development are transition state analogs that
bind to the active site of the c-secretase complex, so as to
inhibit the cleavage of all c-secretase substrates (19). Be-
cause both lymphocytes and stromal cells express proteins
that are c-secretase substrates, it remains to be determined
whether the adverse effects of the inhibitors reﬂect a direct
effect on lymphocytes themselves or an effect on the stromal
cells that direct lymphocyte maturation and/or activation.
Thus, it is important to determine which substrates and cell
types are associated with c-secretase-mediated inhibition of
lymphocyte development and function.
Prominent among the c-secretase substrates is the APP
family, consisting of three highly homologous proteins, APP
and amyloid precursor-like proteins 1 and 2 (APLP1,
APLP2). APLP1 expression is restricted to the nervous sys-
tem (20,21). In contrast, APP and APLP2 mRNA are found
in many tissues, including thymus (20,22–26). Cleavage of
APP, APLP1 or APLP2 by c-secretase releases a small intra-
cellular fragment (27,28) which can associate with numerous
cytosolic proteins including nuclear adaptor protein Fe65
and histone acetyl transferase Tip60 (27,29–32), scaffolding
protein Jnk-interacting protein 1 (JIP1, IB1) (33,34), Grb2
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Gp r o t e i nG 0 (38), ShcA (39) and Notch inhibitory proteins
Numb and Numb-like (40). Although the true physiological
role of APP proteins remains elusive, the intracellular domain
of APP has been shown to modulate phosphoinositide-
mediated calcium ﬂux and MEK/ERK activation (35,41),
trigger apoptosis directly or enhance sensitivity of cells to
other apoptotic stimuli (42), inhibit Notch signaling (40) and
stimulate transcription (27,31,43,44). Notably, intracellular
fragments of APP and Notch can co-localize in nuclear struc-
tures postulated to be sites of active transcription (45), and
it is well established that Notch functions are important for
T cell commitment, differentiation and maturation (46). Given
the potential for cross-talk between APP and Notch in nuclear
signaling and the ﬁnding that APP and APLP2 mRNA are
expressed in lymphoid tissues, it is surprising that APP family
proteins have not yet been studied in the immune system.
Here we have investigated the expression and function of
APP family proteins in developing T cells. We ﬁnd that APP
and APLP2 proteins are expressed in thymus and lymph
nodes (LNs), but exclusively by the stromal cells. These
results preclude a functional role for these proteins in thymo-
cytes themselves. Nevertheless, because thymocyte develop-
ment and selection is absolutely dependent on signals
provided by thymic stromal cells, it was possible that APP/
APLP2 expression by stromal cells was required to support nor-
mal thymocyte development. However, studies of T cell devel-
opment in mice deﬁcient for APP, APLP2 or both revealed that
T cell development proceeded unperturbed. Moreover, these
mice had normal populations of peripheral T and B cells.
While the physiological signiﬁcance of the stromal cell ex-
pression remains to be determined, our results indicate
that the defects in T lymphocyte maturation associated
with c-secretase inhibition do not involve APP family
proteins.
Methods
Mice and genotyping
APP- and APLP2-deﬁcient (germline null mutant) mice have
been previously described (47,48) and were generously
provided by Merck Research Laboratories (Rahway, NJ,
USA) and Robert Cappai (University of Melbourne, Australia),
respectivelyC57BL/6 (B6) mice were obtained from National
Cancer Institute-Frederick. Mice were bred and maintained
under speciﬁc pathogen-free conditions in National Institute
of Allergy and Infectious Diseases (NIAID) Research Animal
Facilities on protocols approved by the NIAID Animal Care
and Use Committee. Mice were genotyped by PCR using the
following primers: APLP2 forward 5#-ctgctgcaggtgg ctctgca-
3#, APLP2 reverse 5#-cag ctctatacaag caaacaag-3#; APP
forward 5#-ctgctgcaggtgg ctctgca-3#, APP reverse 5#-cag
ctctatacaagcaaa caag-3#, and PGKNeo reverse 5#-cattgct-
cagcggt gctgt-3#. The expected fragments are APLP2 wild
type (WT), 400 bp; APLP2
/, 350 bp; APP WT, 250 bp, and
APP
/, 470 bp.
Lymphocyte isolation
Lymphocytes were isolated from thymus and LNs. Single-
cell suspensions were generated using 100 lm nylon mesh
(PGC Scientiﬁcs, Garner, NC, USA). To enrich for mature
HSA
lo/neg thymocytes, single-cell suspensions of total thymo-
cytes were incubated at 37 for 30 min with an anti-HSA
(J11d) culture supernatant, a 1:10 dilution of Cedar Lane
Low-Tox-M Rabbit Complement (Accurate Chemical & Sci-
entiﬁc Corp., Westbury, NY, USA) and DNAse (Calbiochem,
San Diego, CA, USA). After complement-mediated lysis, the
remaining cells were washed twice with media and passed
over a Ficoll gradient to remove dead cells and debris.
Antibodies
Antibodies used for immunoﬂuorescence analysis were pur-
chased from BD PharMingen (San Diego, CA, USA): anti-
CD3eCyC or –APC (145-2C11); anti-CD4–CyC (RM4-5);
anti-CD8–CyC or –APC (53-6.7), anti-CD19–PE (1D3);
anti-CD25–FITC (7D4); anti-CD44–APC, or –biotin (IM7); anti-
CD45–FITC (30-F11); anti-CD45R–CyC (RA3-6B2); anti-TCRcd–
PE (GL3); anti-TCRb–FITC or –PE (H57.597); anti-IgD–FITC
(11-26c.2a). A cocktail used to determine lineage negative
(Lin) thymocytes contained antibodies to CD4, CD8, CD19,
TCRab and TCRcd, all labeled with PE. Anti-CD4–PE (GK1.5)
was purchased from Becton Dickinson Collaborative Technolo-
gies (Bedford, MA, USA). Anti-IgM–biotin was purchased from
Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA).
Annexin V–FITC, propidium iodide and anti-CD8a–FITC or –PE
(CT-CD8) were purchased from Caltag Laboratories (South San
Francisco, CA, USA). Biotin-conjugated antibodies were visual-
ized with streptavidin–Cy5 (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA, USA). For microscopy, a puriﬁed anti-
CD4 (BD PharMingen) was labeled with Alexa488 dye using a
labeling kit (Molecular Probes/Invitrogen, Carlsbad, CA, USA).
Flow cytometry
A single-cell suspension of lymphocytes in HBSS, containing
0.2% BSA and 0.1% NaN3, was incubated with properly di-
luted antibody at 4C for 20 min. After staining, cells were
washed twice with the same buffer and relative ﬂuorescence
was measured by ﬂow cytometry using a FACS Calibur and
Cell Quest Software (Becton Dickinson, San Jose, CA, USA).
In vitro survival assay
Thymocytes were plated at 1–1.5 3 10
6ml
1 in RPMI supple-
mented with 10% FCS and cultured at 37C. The number of
live cells remaining was calculated daily. Live cells were
identiﬁed based upon their ability to exclude Trypan Blue.
Protein lysates and western blotting
Single-cell suspensions or whole lymphoid tissues were
lysed in buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 1 mM Na3VO4 and protease inhibi-
tors (Roche complete tablets; Roche Applied Science, Indi-
anapolis, IN, USA). Samples were incubated on ice for >30
min, inverting every 10 min to mix, and spun for 5 min at
12 000 r.p.m. at 4C. Supernatants were stored at 80C.
For single-cell suspensions, thymus or LNs were crushed
and ﬁltered through 100 lm nylon mesh to remove connec-
tive tissue, resulting in a single-cell suspension containing
>95% CD45
+ hematopoietic cells. For lysates of whole
organs, intact thymus, LN or brain were homogenized in
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composed of both connective tissue and hematopoietic
cells.
Lysates were subjected to PAGE on Novex 8–12%
NuPAGE gels with MES buffer (Invitrogen), and transferred
to Hybond-P PVDF membranes (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA). After blocking with 5% non-fat
dried milk in PBS/0.01% Tween 20, blots were hybridized
overnight at 4C with polyclonal antisera in PBS/0.01%
Tween 20 with 2.5% non-fat dried milk. Anti-APLP1 (CT11)
and anti-APLP2 (D2-II) were purchased from Calbiochem.
Anti-CD3e (M-20) and anti-b-tubulin (H-235) were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Anti-APP/APLP (B10.4) and anti-APP (B62.1) were devel-
oped as previously described for B10.4 (49). Secondary
antibodies were HRP-conjugated anti-rabbit IgG (Roche) or
anti-goat Ig (Jackson ImmunoResearch Laboratories, Inc.).
Blots were developed with ECL western blotting analysis
system (Amersham Pharmacia Biotech) or SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford, IL,
USA).
Histology
Thymuses were ﬁxed with a 4% PFA solution in PBS, then
washed with PBS and treated with 20% sucrose solution in
PBS. After washing, thymuses were immersed in O.C.T. com-
pound (Tissue Tek) for 1 h and snap-frozen using a mixture
of 2-methylbutane (Sigma–Aldrich, St Louis, MO, USA) and
dry ice. Ten micrometer sections were obtained using a cryo-
stat. The sections were ﬁxed with 4% PFA for 15 min, washed
with PBS, incubated with 50 mM NH4Cl for 10 min, washed
with PBS and blocked with a solution containing 5% normal
goat serum, 3% BSA and 0.2% Triton X-100. Sections were in-
cubated overnight with anti-APLP2 (D2-II) in PBS containing
5% normal goat serum and 3% BSA and then washed with
PBS. Sections were stained 4 h with anti-CD4–Alexa-488, anti-
CD8a–APC, and anti-rabbit IgG–Alexa-568 (Cat. no. A-11036,
Molecular Probes) that was used to visualize anti-mouse
Fig. 1. APP and APLP2 are expressed by non-lymphoid cells in thymus and LN. To assess protein expression by western blot analysis, WT mice
and mice deﬁcient for APP (APP
o), APLP2 (APLP2
o) or APP/APLP2 double-deﬁcient (Dbl
o) mice were used to obtain (A) cell suspensions of
thymocytes and intact brain, (B) cell suspensions of total or HSA
neg/lo thymocytes, intact thymus (which include stromal cells) or brain or (C) cell
suspensions of B6 LNs (pre-sort) electronically sorted for T (TCRab
+) or B (CD19
+) cells, intact B6 LNs (which include stromal cells) or intact
brain. Blots were hybridized with antisera against APP/APLP, APP, APLP1 or APLP2, as designated, or with anti-CD3e and anti-b-tubulin for
loading controls.
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ProLong Antifade (Molecular Probes), and immunoﬂuores-
cence was analysed using a Leica LSR confocal microscope.
Statistical analyses
All two-tailed Student’s t-tests were conducted using InStat
Instant Biostatistics (GraphPad Software; San Diego, CA,
USA). Error bars represent SEM.
Results
APP and APLP2 proteins are expressed in thymus and LNs
APP and APLP2 mRNA are expressed in thymus (20,22–26).
To determine which thymic cell type(s) express APP family
proteins, APP, APLP1 and APLP2 proteins were analysed by
western blotting. Lysates made from thymus cell suspen-
sions or intact brain of adult APP
+/, APP
/, APLP2
/ or
APP
/APLP2
/ mice were blotted with polyclonal rabbit
sera raised against APP, APLP2 or APLP1. As expected, all
three homologues were highly expressed in brain (Fig. 1).
Consistent with previous reports that APLP1 expression is
restricted to the nervous system, APLP1 was never observed
in thymus lysates. Surprisingly, APP was not detected in thy-
mocyte lysates under any conditions tested. In most analy-
ses, APLP2 was also undetectable. However, in cases
where a super sensitive extended duration substrate and
long exposure times were used (see Methods), a faint
APLP2 band was visualized in lysates made from large num-
bers of thymocytes. This result was consistent with either ex-
tremely low expression by many thymocytes or high
expression by a minor fraction of cells, for example, by ma-
ture CD4
+CD8
 or CD4
 CD8
+ single-positive (SP) thymo-
cytes which account for ;10% of total thymocytes.
Since thymocytes gradually downregulate expression of
HSA (CD24) as they mature (50), we used this marker to iso-
late mature thymocytes for assay of APLP2 expression. Thy-
mocytes of APP
+/, APP
/ or APLP2
/ mice were
depleted of immature HSA
hi cells using anti-HSA antibody
(J11d) and rabbit complement. Prior to enrichment, thymo-
cyte populations contained ;10% CD4 or CD8 SP thymo-
cytes. After complement-mediated lysis, thymocytes were
>90% mature SP (data not shown). As shown in Fig. 1(B),
APLP2 expression was not enriched in lysates of SP thymo-
cytes, making it unlikely that the faint band was due to a late
onset of APLP2 expression in the most mature thymocytes.
Very few thymic stromal cells are recovered in thymocyte
cell suspensions, whereas virtually all thymocytes and stro-
mal cells are recovered if the intact thymus organ is used
for preparing protein lysates. Thus, it was conceivable that
the low level of APLP2 detected in lysates of thymocyte sus-
pensions derived only from stromal cells. Indeed, lysates
blotted for APP or APLP2 revealed a strong band for APLP2 us-
ing whole thymus of B6, APP
/ or recombination-activating
gene
/(RAG
/) mice and only a faint band for APP using
whole thymus of B6, APLP2
/ or RAG
/ mice (Fig. 1B).
These results suggested that thymic stromal cells express
high levels of APLP2 and low levels of APP proteins, whereas
thymocytes express neither family member.
To conﬁrm the expression of APLP2 by thymus stromal
cells, histological sections of WT B6 thymuses were stained
with the same anti-APLP2-speciﬁc antisera used for western
blotting in Fig. 1 and imaged using confocal microscopy
(Fig. 2). Thymus cortex was identiﬁed by the presence of
Fig. 2. APLP2 expression is localized to thymic stroma. Thymuses of WT B6 mice were ﬁxed, sectioned and stained for co-expression of CD4
(green), CD8 (blue) and APLP2 (red). (A) The thymus cortex was identiﬁed by the presence of densely packed thymocytes co-expressing both
CD4 and CD8. (B) Same image as in (A), showing immunoﬂuorescence from anti-CD4 and anti-APLP2. (D) The thymus medulla was identiﬁed by
the presence of less densely packed thymocytes expressing either CD4 or CD8. (E) Same image as in (D), showing immunoﬂuorescence from
anti-CD4 and anti-APLP2. (C and F) Serial sections of A/B or D/E, control showing immunoﬂuorescence of anti-CD4 and secondary Alexa-586-
labeled anti-rabbit-IgG without the primary anti-APLP2 antibody. Images were collected at 363 magniﬁcation on a Leica LSR confocal
microscope.
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CD8 (Fig. 2A). The thymus medulla was identiﬁed by the
presence of less densely packed thymocytes expressing ei-
ther CD4 or CD8 (Fig. 2D). By these analyses, APLP2 was
expressed throughout the thymus by both the cortical and
medullary stromal cells (Fig. 2B,E). Consistent with the west-
ern blotting data, no co-localization of CD4 and APLP2 ex-
pression was observed, conﬁrming that APLP2 expression
was restricted to non-T lineage cells.
To determine the expression pattern of APP and APLP2 in
secondary lymphoid tissue, lysates made from B6 LNs were
blotted for these proteins (Fig. 1C). The expression pattern
of APP and APLP2 in LNs was similar to that of thymus. Both
proteins were undetectable in lysates prepared from LN cell
suspensions, or highly puriﬁed populations of T or B cells.
However, these proteins were present in lysates made from
intact, whole LNs, indicating that APP and APLP2 were
derived from stromal cells. Therefore, the ﬁndings are
Fig. 3. APP and/or APLP2 are not required for normal thymocyte development from adult precursors. (A) Total thymus cellularity was calculated
for 4- to 12-week old WT (APP
+ or APLP2
+) and APP
/ and/or APLP2
/ mice, as indicated. Asterisk denotes signiﬁcance by t-test, P = 0.02. (B)
Cells were gated for CD45
+ and analysed for expression of CD4 and CD8a (top), gated to exclude cells expressing CD4, CD8a, CD19, TCRab
and TCRcd (Lin) and analysed for expression of CD44 and CD25 (middle) or gated for CD3
+ and analysed for expression of TCRab and TCRcd
(bottom). The data are representative of at least ﬁve mice analysed for each genotype.
APP family proteins are dispensable for lymphopoiesis 1167consistent with previous reports of APP and APLP2 mRNA ex-
pression in lymphoid organs, but results here reveal that this
expression can be attributed to non-lymphoid stromal cells.
Neither APP nor APLP2 are required for lymphocyte
development from adult precursors
While we were unable to detect APP family protein expression
in thymocytes, the possibility remained that these proteins per-
formed some direct or indirect function in T cell development.
Of relevance, thymic stromal cells are essential for promoting
T cell differentiation; however, the signals they provide to de-
veloping thymocytes have not been fully deﬁned. Therefore,
the signiﬁcance of high APLP2 expression by thymic stromal
cells (Figs 1 and 2) was of particular interest. To pursue this
issue, we investigated thymocyte development in mice deﬁ-
cient for APP family proteins. Mice with germline mutations
in either APP or APLP2 have been described (47,48,51–53)
and are grossly normal. In contrast, doubly deﬁcient
APP
/APLP2
/ mice have >80% neonatal mortality rate,
and those mice that survive to adulthood are sterile and have
multiple neurological and behavioral abnormalities (48,52).
While the central nervous system of APP- and/or APLP2-
deﬁcient mice have been extensively studied (47,48,51–53),
lymphocytes of these mice have not been characterized.
The more severe phenotype of double-deﬁcient mice for
APP and APLP2 demonstrates that these proteins are at
least somewhat functionally redundant. To characterize thy-
mocyte development in the absence of APP and APLP2,
APP
+/APLP2
/ mice were intercrossed to generate APP
/
APLP2
/ animals. APP
/APLP2
/ pups were born with
less than the predicted 25% Mendelian frequency
(20:54:15); moreover, very few survived to weaning at 3
weeks of age. Of 260 mice from 50 litters genotyped, only 5
APP
/APLP2
/ mice survived to adulthood (94:161:5).
Compared with control littermates, the mice that survived
were smaller in overall body size and weight, failed to breed,
appeared agitated and exhibited neurological problems
such as forelimb weakness, spinning and difﬁculty righting.
Thymus cellularity of 4- to 12-week old mice, deﬁcient for
either APP or APLP2, was not signiﬁcantly different from that
of their WT littermates, but absolute numbers were decreased
in the APP
/APLP2
/ mice (Fig. 3A and Table 1). However,
when mice are stressed by poor health, it is common for thy-
mus cellularity to be reduced due to an increased production
of endogenous steroids. Although the double-deﬁcient mice
had a global reduction in thymocyte numbers, there was no
indication of a developmental block by subset or linage anal-
ysis This interpretation was supported by the fact that the rel-
ative proportion of all subsets/lineages were comparable in
APP and/or APLP2 mice (Table 1). Mean percentages of thy-
mocytes at each distinct stage of development, double nega-
tive (DN, CD4CD8), double positive (DP, CD4+CD8+)a n d
CD4 and CD8 SP, were all normal (Fig. 3B, top panels), and
in the absence of APP and/or APLP2, there was no evidence
of an accumulation of DN thymocytes. The relative contribu-
tion of each DN subset, DN1 (CD44+CD25), DN2
(CD44+CD25+), DN3 (CD44CD25+) and DN4 (CD44
CD25) was unaffected (Fig. 3B, middle panels), and in
APP
/APLP2
/ mice, the absolute number of all four sub-
sets was similarly reduced (Table 1). WT and mutant mice
Table 1. Analysis of absolute cell number and relative proportion of thymocyte subsets in adult mice deﬁcient in amyloid
precursor family proteins
a
Subset WT APP
/ APLP2
/ APP
/APLP2
/
Number of thymocytes (310
7)
Total 22.97 6 1.10 20.24 6 1.44 22.12 6 2.09 9.14 6 1.58*
DN 0.51 6 0.02 0.45 6 0.03 0.47 6 0.04 0.17 6 0.04*
DP 20.21 6 1.00 18.24 6 1.27 20.29 6 2.10 7.98 6 1.32*
CD4 SP 1.64 6 0.09 1.51 6 0.10 1.60 6 0.17 0.78 6 0.20*
CD8 SP 0.60 6 0.04 0.50 6 0.03 0.54 6 0.06 0.21 6 0.05*
Number of thymocytes (310
6)
cd 0.30 6 0.02 0.30 6 0.02 0.30 6 0.05 0.11 6 0.00*
Total Lin
 5.47 6 0.33 5.44 6 0.95 4.12 6 0.73 2.37 6 0.67*
DN1 0.48 6 0.11 0.36 6 0.15 0.33 6 0.09 0.13 6 0.04*
DN2 0.45 6 0.07 0.38 6 0.08 0.24 6 0.04 0.15 6 0.06*
DN3 2.38 6 0.41 2.16 6 0.75 1.61 6 0.55 0.98 6 0.34*
DN4 2.15 6 0.10 2.45 6 0.30 1.91 6 0.22 0.11 6 0.31*
Percent of CD45
+ thymocytes
cd 1.49 6 0.07 1.36 6 0.07 1.51 6 0.07 1.91 6 0.94
DN 2.25 6 0.07 2.21 6 0.12 2.13 6 0.12 1.75 6 0.17
DP 87.96 6 0.26 87.99 6 0.28 88.51 6 0.84 88.44 6 1.89
CD4 SP 7.09 6 0.13 7.33 6 0.14 7.00 6 0.38 7.61 6 1.74
CD8 SP 2.61 6 0.09 2.48 6 0.10 2.36 6 0.15 2.16 6 0.27
Percent of Lin
 thymocytes
DN1 8.97 6 2.05 6.21 6 1.85 7.68 6 1.38 5.71 6 1.18
DN2 8.13 6 1.06 8.04 6 2.63 6.17 6 0.70 6.79 6 3.02
DN3 42.47 6 5.55 36.39 6 5.55 35.07 6 6.26 39.05 6 3.85
DN4 40.03 6 6.42 47.38 6 6.42 50.09 6 5.83 48.48 6 6.55
aValues represent arithmetic means 6 SEM; *P < 0.03; for WT n = 32, APP
/ n = 26, APLP2
/ n = 18, and APP
/APLP2
/ n = 5, with the
exception of Lin
 (lineage negative, as described in Methods) n = 5 for each genotype.
1168 APP family proteins are dispensable for lymphopoiesisgenerated TCR
hi mature thymocytes with similar frequency
and the percentages of ab or cd thymocytes within the TCR
hi
population were equivalent (Fig. 3B, bottom panels). Thus, T
cell development proceeded normally with no evidence of
a block at any stage, indicating that neither APP nor APLP2
are required for thymocyte maturation.
In the periphery, LNs from APP
/, APLP2
/ and APP
/
APLP2
/ mice all contained mature T and B lymphocytes
at the expected frequency (Fig. 4). The CD3
+ T cell popula-
tions were normal, composed primarily of ab T cells with
<2% of cells expressing TCRcd (data not shown). Within the
ab T lineage, CD8 and CD4 T cells were present at normal
frequencies, and LN B cells had the expected naive
IgM
+IgD
+ phenotype. Taken together, these results indicate
no role for APP family members in the development of lym-
phocytes originating from adult precursors.
Neither APP nor APLP2 are required for thymocyte
development from fetal precursors
Several groups have utilized in vitro fetal thymus organ cul-
ture systems to assess the effects of c-secretase inhibitors
on thymocyte development (1,2). It is noteworthy in this
regard that thymocytes developing in embryonic day 14–
15.5, fetal thymus are derived from fetal liver precursors,
whereas thymocytes of adults are derived from bone mar-
row. Thus, while APP and/or APLP2 were not needed for
adult thymocyte development, it was possible that these pro-
teins could be required for fetal development.
To assess T cell development from fetal liver precursors,
thymocytes isolated from newborn APP- APLP2-deﬁcient
pups were analysed. APP
/APLP2
/ pups were born with
less than the predicted Mendelian frequency, and APP
/
Fig. 4. Mature T and B cells appear normally in LNs in the absence of APP and/or APLP2. LN cells were gated for CD45
+ and analysed for
expression of CD3 and CD19 (ﬁrst row), gated for TCRab
+ cells and analysed for expression of CD4 and CD8a (second row) or analysed for
expression of CD19 and IgM (third row). Cells co-expressing CD19 and IgM were analysed for expression of IgD (fourth row). The data are
representative of at least three mice for each genotype.
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/ neonates often had less milk in their stomach con-
sistent with neurological deﬁcits impairing their ability to
suckle. In contrast to adult mice, only subtle differences in
thymus cellularity were observed in the newborns (P > 0.05)
(Fig. 5A). Phenotypic analyses of newborns revealed that all
CD4/CD8 thymocyte subsets, as well as mature TCRab
+ or
TCRcd
+ thymocytes, were normal (Fig. 5B), similar to adults.
Therefore, APP and APLP2 are dispensable for T cell matu-
ration from fetal or adult precursors.
APP or APLP2 deﬁciency does not confer a survival
advantage to thymocytes
APP is a positive regulator of programmed cell death.
Forced expression of the intracellular domain of APP lowers
the threshold for Fas-associated death in Jurkat T cells and
induces apoptosis in HeLa and MCF7 cells (42). To deter-
mine sensitivity to programmed cell death, thymocytes of
APP- APLP2-deﬁcient mice were analysed directly ex vivo
or at various times after culture in media in the absence of
stromal cells or exogenous cytokines. The frequency of thy-
mocytes undergoing apoptosis directly ex vivo or throughout
the 4-day culture period was similar as determined by
Annexin V and propidium iodide staining (Fig. 6A, and data
not shown). Based on the ability to exclude Trypan Blue, ab-
solute numbers of live cells remaining after culture were also
assayed. At no time point was the mean number of live
thymocytes recovered signiﬁcantly different (P > 0.26)
(Fig. 6B). Thus, in spite of a putative pro-apoptotic function
for these proteins, the absence of APP and/or APLP2 did
not confer a survival advantage to thymocytes.
Discussion
Studies using fetal thymus organ cultures demonstrate that
c-secretase inhibitors interrupt thymocyte maturation at sev-
eral points (1,2). First, the transition of DN to DP thymocytes
is impaired, and in late T cell development, the maturation
of CD8 SP thymocytes is impeded. The end result is re-
duced thymus cellularity and an accumulation of DN thymo-
cytes. These studies indicate that the activity of one or more
of the c-secretase substrates is important for T cell develop-
ment. Moreover, they suggest that c-secretase inhibitors, de-
veloped for treatment of Alzheimer’s disease, could have
immunosuppressive effects. APP family proteins were poten-
tially the substrates affected because of the functions as-
cribed to these proteins as well as their reported expression
in thymus. Thus, identifying c-secretase substrates that oper-
ate in thymocyte development is important for elucidating the
signals that drive differentiation and control cell fate. More
signiﬁcantly, identifying the target activities of c-secretase
inhibitors could aid in the development of more speciﬁc drugs
for treating Alzheimer’s disease with fewer immunosuppres-
sive side effects.
From our results, it can be inferred that the inhibitors
used in fetal thymus organ culture must have interfered with
the processing of c-secretase substrates other than APP/
APLP2. We ﬁnd that newborn mice deﬁcient for APP and/or
APLP2 had normal thymus cellularity and CD4/CD8 sub-
sets. Moreover, adult mutant mice had a normal frequency
of mature T and B cells in LNs. Efﬁcient thymocyte develop-
ment in APP- and/or APLP2-deﬁcient mice, coupled
with the absence of detectable APP, APLP1 or APLP2 pro-
tein expression by thymocytes or peripheral lymphoid
cells, demonstrate that APP family members do not play
a critical role in murine lymphocyte development. An
Fig. 5. APP and/or APLP2 are not required for normal thymocyte
development in neonates. (A) Total thymus cellularity was calculated
for newborn mice (P-values revealed no signiﬁcant differences). (B)
Thymocytes were gated for CD45
+ and analysed for expression of
CD4 and CD8 (top) or for CD3
+ and analysed for expression of TCRab
and TCRcd (bottom). Because the APLP2
/ were equivalent to WT
mice by every criteria tested, these mice were used as littermate
controls since they were generated in the same cross.
1170 APP family proteins are dispensable for lymphopoiesisimportant implication of these results is that pharmacologi-
cal inhibitors that speciﬁcally inhibit cleavage of APP
should not adversely affect lymphocyte development.
The ﬁrst c-secretase inhibitor described in 1998 was a tran-
sition state analog that worked by binding to and blocking
the active site of the c-secretase complex (19). Since then,
numerous other c-secretase inhibitors have been developed
that work by a variety of mechanisms. The data presented
here suggest that inhibitors that speciﬁcally interfere with
c-secretase-mediated APP cleavage are unlikely to have im-
munosuppressive side effects. Similarly, inhibitors that inter-
fere with the ﬁrst (BACE-mediated) cleavage of APP (54,55),
Fig. 6. Absence of APP and/or APLP2 confers no survival advantage on thymocytes. (A) Thymocytes were stained for Annexin V and propidium
iodide ex vivo, or at various times after culture. (B) The number of live thymocytes harvested daily from cell culture was determined by Trypan
Blue exclusion. Data represent the mean percentage of live cells remaining 6SEM. P > 0.2 for all time points.
APP family proteins are dispensable for lymphopoiesis 1171rather than the second c-secretase-mediated cleavage, are
unlikely to have immunosuppressive side effects on lympho-
cyte development or function. Consistent with this notion,
BACE-deﬁcient animals have no reported phenotype
(56,57).
Our initial experiments using lysates of thymocyte cell
suspensions revealed that mouse thymocytes do not ex-
press signiﬁcant levels of APP or APLP2 protein. These
ﬁndings were surprising in light of previous reports of
mRNA expression in thymus (20,22–26). However, the ear-
lier studies examined RNA prepared from intact thymus
which recovers most of the stromal cells as well as the
thymocytes. This discrepancy was reconciled when we pre-
pared lysates from intact thymus or stained sections of
frozen thymus. In assays that efﬁciently recover thymic stro-
mal cells, it was clear that APLP2 protein was highly
expressed and APP protein, at much lower levels. The latter
results are consistent with ﬁndings that APP and APLP2
transcripts are both expressed in mouse thymus, with
APLP2 > APP mRNA (23). Notably, in rats APP is reported
to be expressed by astrocytes and microglia (22). The ex-
pression of APP in these myeloid cell types is consistent
with our ﬁnding of APP and APLP2 in non-lymphoid cells of
thymus and LN.
Using newly developed antisera speciﬁc for each member
of the APP family, we were able to show for the ﬁrst time that
APP, APLP1 and APLP2 proteins are not expressed in
mouse lymphocytes. Consistent with these data, APP mRNA
is not detected in rat spleen (58). Most reports agree that
human peripheral blood lymphocytes do not express APP
constitutively, but APP can be induced in response to mito-
genic stimulation (22,59). Some human T-lymphoma cell
lines express APP, while other T cell lines do not. However,
several issues must be considered when interpreting these
data. Studies conducted prior to the cloning of APLP2 used
antisera raised against the C-terminus of APP. Many of those
antisera were later found to cross-react on APLP2 (23), mak-
ing it unclear which protein(s) were detected. Moreover, in
light of our present ﬁndings that APP and APLP2 are
expressed by non-lymphoid cells in thymus and LN, the con-
tribution of non-lymphoid cell in those preparations compli-
cates any conclusions regarding lymphocyte expression. If,
however, the dichotomy in APP/APLP2 expression patterns
by murine and human lymphocytes is conﬁrmed, then there
may be fundamental differences in APP biology between
mice and humans that must be taken in to account when de-
veloping experimental models for studying Alzheimer’s dis-
ease in mice.
The signiﬁcance of APP family protein expression in thy-
mic stromal cells is unclear. Although thymic stromal cells
provide essential signals for thymocyte maturation, T cells of
APP-/APLP2-deﬁcient mice develop normally. Identifying
a role for APP and APLP2 in stromal cells could help in de-
termining the physiological function of APP family members.
Of relevance, a punctate staining pattern of APP on the cell
surface of neurons in rat brain led to the hypothesis that
APP mediates cell–cell or cell–matrix interactions (60).
Therefore, if ligands of APP and APLP are discovered, it
would be of interest to determine whether they are
expressed by thymocytes.
APP and APLP2 mRNA have been found in all tissues ex-
amined to date. However, because of a potential role in Alz-
heimer’s disease, most of the work investigating APP
associations has been conducted using neuronal cells. As
a result, many of the proteins found to associate with the in-
tracellular domain of APP are speciﬁcally expressed by neu-
rons. For example, G0 is a brain-speciﬁc G protein (61), and
expression of ShcC is restricted to the central nervous sys-
tem (62). The intracellular domain of APP also associates
with the nuclear adaptor protein Fe65 and Tip60 to form
a complex that stimulates transcription (29–31). In this re-
port, we have shown that APLP2 is highly expressed by stro-
mal cells in both primary and secondary lymphoid tissues. It
remains to be determined what proteins interact with APP/
APLP2 in non-neuronal cell types and the function of these
associations especially since the speciﬁc outcome of APP
cleavage has been shown to be cell type dependent (42).
We have demonstrated that APP family proteins are not
expressed in T lineage cells. This ﬁnding effectively
excludes these proteins from the list of c-secretase sub-
strates that are required for normal T cell development.
There are, however, several other c-secretase substrates to
be considered. Expression of substrates, ErbB4, Nectin-1a
and LRP, by lymphocytes has not been reported, but imma-
ture T cells do express E-cadherin and CD44. Although
E-cadherin plays a critical role in the development of a func-
tional thymic environment, it is not required for thymocyte
maturation within an established thymus microenvironment
(63). Moreover, T and B cells develop and function normally
in CD44-deﬁcient mice (64). Recent data suggest that the
most likely explanation for c-secretase-mediated inhibition of
thymocyte development is due to interference with Notch
signaling. It is well established that Notch is expressed by
thymocytes (60,65–68). In addition, Notch signaling is re-
quired for commitment of lymphoid precursors to the T cell
lineage and for later stages of T cell development, including
TCRb selection of thymocytes and functional differentiation
of peripheral CD4 helper cells (7,69–73).
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